Jessica T. Leonard

Hematology

3485 S Bond Ave
Portland, OR 97239

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 50 publications

Lineage switch from T- ALL to a clonal related T/myeloid leukemia following treatment with CD38 directed therapy.

Lineage switch from T- ALL to a clonal related T/myeloid leukemia following treatment with CD38 directed therapy.

Journal: Leukemia & lymphoma

Published: June 01, 2026

Allogeneic Hematopoietic Cell Transplant Following Standard of Care Brexucabtagene Autoleucel in Adults with B-Cell Acute Lymphoblastic Leukemia: Results from the Real-World Outcomes Collaborative of Chimeric Antigen Receptor T in Adult Acute Lymphoblastic Leukemia.

Allogeneic Hematopoietic Cell Transplant Following Standard of Care Brexucabtagene Autoleucel in Adults with B-Cell Acute Lymphoblastic Leukemia: Results from the Real-World Outcomes Collaborative of Chimeric Antigen Receptor T in Adult Acute Lymphoblastic Leukemia.

Journal: Transplantation and cellular therapy

Published: April 21, 2026

Improved Outcomes with TKI Maintenance Following Brexucabtagene Autoleucel in Philadelphia-chromosome ALL.

Improved Outcomes with TKI Maintenance Following Brexucabtagene Autoleucel in Philadelphia-chromosome ALL.

Journal: Blood advances

Published: April 09, 2026

Improved outcomes with TKI maintenance after brexucabtagene autoleucel in Philadelphia chromosome ALL.

Improved outcomes with TKI maintenance after brexucabtagene autoleucel in Philadelphia chromosome ALL.

Journal: Blood advances

Published: April 09, 2026

Consensus recommendations for CAR T-cell administration in adult acute lymphoblastic leukemia: a modified Delphi study.

Consensus recommendations for CAR T-cell administration in adult acute lymphoblastic leukemia: a modified Delphi study.

Journal: Blood

Published: February 20, 2026

Consensus Recommendations for CAR T-Cell Administration in Adult Acute Lymphoblastic Leukemia: a Modified Delphi Study.

Consensus Recommendations for CAR T-Cell Administration in Adult Acute Lymphoblastic Leukemia: a Modified Delphi Study.

Journal: Blood

Published: February 20, 2026

Early neurologic response predicts outcomes after anakinra for immune effector cell-associated neurotoxicity syndrome.

Early neurologic response predicts outcomes after anakinra for immune effector cell-associated neurotoxicity syndrome.

Journal: Blood advances

Published: February 18, 2026

Blinatumomab Nonresponse Correlates with Poor Survival After Brexucabtagene.

Blinatumomab Nonresponse Correlates with Poor Survival After Brexucabtagene.

Journal: Blood

Published: September 19, 2025

Blinatumomab nonresponse correlates with poor survival after brexucabtagene autoleucel in B-cell ALL.

Blinatumomab nonresponse correlates with poor survival after brexucabtagene autoleucel in B-cell ALL.

Journal: Blood

Published: September 19, 2025

Identifying Drug Combination Strategies for ZMYM2: FGFR1 Fusion Positive Leukemia.

Identifying Drug Combination Strategies for ZMYM2: FGFR1 Fusion Positive Leukemia.

Journal: Precision oncogenomics

Published: August 29, 2025

Results of a phase 1 trial testing ruxolitinib plus venetoclax in patients with relapsed/refractory acute myeloid leukemia.

Results of a phase 1 trial testing ruxolitinib plus venetoclax in patients with relapsed/refractory acute myeloid leukemia.

Journal: Blood neoplasia

Published: July 02, 2025

Blinatumomab and better BCR::ABL1 inhibition begets better bone marrow transplant outcomes.

Blinatumomab and better BCR::ABL1 inhibition begets better bone marrow transplant outcomes.

Journal: Haematologica

Published: May 19, 2025

Showing 1-12 of 50

Last Updated: 09/26/2026